← DiaMedica Therapeutics Inc. (DMAC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
DiaMedica Therapeutics Inc. (DMAC)
Pharmaceutical Preparations · market cap $400M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
DiaMedica Therapeutics (DMAC) is a clinical-stage pharma with 27 employees and a ~$429M market cap built almost entirely around a Phase 3 trial of recombinant human tissue kallikrein (DM199) in acute ischemic stroke, with a readout estimated for December 2025. A secondary Phase 2 program in chronic kidney disease rounds out the pipeline, but the company's survival is a near-term question: reported cash of $4.9M implies a runway of roughly 1.6 months, making imminent capital raises near-certain.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · Recombinant human tissue kallikreinimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DM199 | Phase 2 | Kidney Diseases |
| Recombinant human tissue kallikrein | Phase 3 | Acute Stroke |
Price & technical context
3-month
+9.6%
6-month
+30.1%
12-month
+21.7%
52-wk range
$5.33–$9.39
vs 50-day MA
+21.7%
vs 200-day MA
+17.6%
Realized vol
64.1%
Max drawdown
-49.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DMAC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.